Stacey Molinere
Psychiatric/Mental Health · Lake Charles, LANPI 1992743892
Payments from drug & device makers
Across 268 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$404
- Teva Pharmaceuticals USA, Inc.$355
- Otsuka America Pharmaceutical, Inc.$274
- Alkermes, Inc.$258
- plus $928 from 15 others
What the payments were for
- Food & beverage$4,55797%
- Education$1583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 85 | $1,367 |
| AbbVie | 75 | $1,130 |
| Vanda Pharmaceuticals Inc. | 15 | $404 |
| Teva Pharmaceuticals USA, Inc. | 16 | $355 |
| Otsuka America Pharmaceutical, Inc. | 14 | $274 |
| Alkermes, Inc. | 16 | $258 |
| Sunovion Pharmaceuticals Inc. | 10 | $185 |
| Indivior Inc. | 7 | $145 |
| Johnson & Johnson | 4 | $118 |
| Supernus Pharmaceuticals, Inc. | 5 | $99 |
| Axsome Therapeutics, Inc. | 5 | $89 |
| Neurocrine Biosciences, Inc. | 3 | $80 |
| Lundbeck LLC | 3 | $52 |
| Lilly USA, LLC | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $15 |
| Braeburn Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Corium, LLC | 1 | $13 |
How this compares
$4,716 in reported general payments places this provider in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 13 | $1,897 |
| Oxcarbazepine | 43 | $1,184 |
| Doxepin Hcl | 22 | $599 |
| Mirtazapine | 39 | $358 |
| Trazodone Hcl | 50 | $302 |
| Buspirone Hcl | 42 | $255 |
| Aripiprazole | 16 | $247 |
| Duloxetine Hcl | 26 | $230 |
| Sertraline Hcl | 24 | $217 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $200 |
| Bupropion Hcl SrBupropion Hcl | 15 | $198 |
| Quetiapine Fumarate | 31 | $195 |
| Olanzapine | 17 | $188 |
| Hydroxyzine Pamoate | 14 | $187 |
| Bupropion XlBupropion Hcl | 17 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $30 | $18817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lake Charles
- Sattaria DilksLake Charles$57K
- Michelle DyerLake Charles$33K
- Erica HessiferLake Charles$13K
- Candyce BrownLake Charles$13K
- Bethanne CarsonLake Charles$12K
- Morgan UnserLake Charles$9K
- Eric RachalLake Charles$9K
- Lori KayLake Charles$9K
- Valarie ClarkLake Charles$8K
- Julie DyrekLake Charles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.